Partially saturated tricyclic compounds and methods of making and using same

Abstract

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

What is claimed is: 
     
         1 .- 44 . (canceled) 
     
     
         45 . A tricyclic compound represented by: 
       
         
           
           
               
               
           
         
       
       wherein:
 D 2  is a partially unsaturated heterocyclic ring wherein X 2  is  + —O—CH 2 —*; wherein the  +  and * indicate the attachment points of X 2  as indicated in Formula IV; 
 R B1  is selected from the group consisting of hydrogen and C 1-3 alkyl; wherein C 1-3 alkyl is optionally substituted by a group selected from OH, C1 2 alkoxy or one or more fluorine atoms; 
 R A1  is selected, independently for each occurrence, from hydrogen or halogen; 
 n is 0, 1, or 2; 
 R A2  is selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl and C 1-6 alkoxy; wherein C1 6 alkyl, C 2-6 alkenyl and C1 6 alkoxy may optionally be substituted by one or more groups R P ; 
 R P  is independently selected, for each occurrence, from the group consisting of halogen, hydroxyl, C 1-6 alkoxy, R i R j N- and R i R j N-carbonyl-; 
 R i  and R j  are selected independently for each occurrence from the group consisting of hydrogen and C 1-4 alkyl; wherein C 1-4 alkyl may be optionally substituted by one or more substituents selected from fluorine, hydroxyl and C 1-3 alkoxy; 
 or a pharmaceutically acceptable salt or stereoisomer thereof. 
 
     
     
         46 . The tricyclic compound of  claim 45 , wherein R B1  is selected from hydrogen or methyl. 
     
     
         47 . The tricyclic compound of  claim 45 , wherein R A1  is selected from hydrogen or fluorine. 
     
     
         48 . The tricyclic compound of  claim 45 , wherein R A2  is C 2-6 alkenyl substituted by R i R j N—. 
     
     
         49 . The tricyclic compound of  claim 45 , wherein R A2  is (Z)-3-(N,N-diethylamino)prop-1-enyl. 
     
     
         50 . The tricyclic compound of  claim 45 , wherein the compound is represented by: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or stereoisomer thereof. 
     
     
         51 . A pharmaceutically acceptable composition comprising a tricyclic compound represented by: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient. 
     
     
         52 . A tricyclic compound represented by: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.